Grant name: Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV
Funding organization: National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Total funding amount: $2.5 million
Funding duration: Up to 5 years
Primary objective: To examine protein interaction networks in HIV-infected microglia and their role in SUD and HIV comorbidity.
This is a reissue of RFA-DA-25-014.
The grant is part of NIH's efforts to address the intersection of HIV and substance use disorders.
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits (with and without 501(c)(3) status)
For-Profit Organizations
Small Businesses
Local, State, County, City, and Township Governments
Indian/Native American Tribal Governments (both recognized and non-recognized)
Federal Government Agencies
U.S. Territories or Possessions
Other organizations including Independent School Districts, Public Housing Authorities, Faith-based Organizations, and Foreign Organizations.
Organizations must register with System for Award Management (SAM), eRA Commons, and Grants.gov before applying.
Investigate protein interaction networks in microglia affected by HIV and SUD.
Utilize quantitative analytical approaches and in vivo models for research.
Generate foundational knowledge for potential therapeutic interventions targeting HIV and SUD comorbidity.
Applicants should demonstrate expertise in quantitative protein profiling and relevant methodologies.
Application budgets are not limited but must reflect actual project needs.
Open Date: July 14, 2025
Application Deadline: July 14, 2025
Earliest Start Date: August 14, 2025
Expiration Date: August 15, 2025
Applicants must comply with NIH Grants Policy Statement and other federal regulations.
Applications must be submitted electronically via Grants.gov or NIH ASSIST.
A letter of intent is encouraged but not required.